Biohaven signs Ono Pharma licensing for BHV-1300 in Asia
Biohaven said it entered a strategic licensing agreement with Ono Pharma covering extracellular IgG degraders in Japan and select Asian regions, with lead candidate BHV-1300 in Phase 3 for Graves' disease.
Story updates
08:00:57 AM UTC
SquawkNews
BHVN - Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
08:03:06 AM UTC
SquawkNews
ONO PHARMACEUTICAL CO., LTD. TSE:4528